Literature DB >> 17036244

Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience.

Panteleimon Giannakopoulos1, Gabriel Gold, Enikö Kövari, Armin von Gunten, Anouk Imhof, Constantin Bouras, Patrick R Hof.   

Abstract

The progressive development of Alzheimer disease (AD)-related lesions, such as neurofibrillary tangles (NFT), amyloid deposits and synaptic loss, and the occurrence of microvascular and small macrovascular pathology within the cerebral cortex are conspicuous neuropathologic features of brain aging. Recent neuropathologic studies strongly suggested that the clinical diagnosis of dementia depends more on the severity and topography of pathological changes than on the presence of a qualitative marker. However, several methodological problems, such as selection biases, case-control design, density-based measures and masking effects, of concomitant pathologies persisted. In recent years, we performed several clinicopathologic studies using stereological counting of AD lesions. In order to define the cognitive impact of lacunes and microvascular lesions, we also analyzed pure vascular cases without substantial AD pathology. Our data revealed that total NFT numbers in the CA1 field, cortical microinfarcts and subcortical gray matter lacunes were the stronger determinants of dementia. In contrast, the contribution of periventricular and subcortical white matter demyelinations had a modest cognitive effect even in rare cases with isolated microvascular pathology. Importantly, in cases with pure AD pathology, more than 50% of Clinical Dementia Rating scale variability was not explained by NFT, amyloid deposits and neuronal loss in the hippocampal formation. In cases with microvascular pathology or lacunes, this percentage was even lower. The present review summarizes our data in this field and discusses their relevance within the theoretical framework of the functional neuropathology of brain aging and with particular reference to the current efforts to develop standardized neuropathological criteria for mixed dementia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17036244     DOI: 10.1007/s00401-006-0144-y

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  44 in total

1.  Cerebrovascular disease, β-amyloid, and cognition in aging.

Authors:  Natalie L Marchant; Bruce R Reed; Charles S DeCarli; Cindee M Madison; Michael W Weiner; Helena C Chui; William J Jagust
Journal:  Neurobiol Aging       Date:  2011-11-01       Impact factor: 4.673

2.  Toward a pathological definition of vascular dementia.

Authors:  Lea Tenenholz Grinberg; Helmut Heinsen
Journal:  J Neurol Sci       Date:  2010-12-15       Impact factor: 3.181

Review 3.  Nonhuman primate models of Alzheimer-like cerebral proteopathy.

Authors:  Eric Heuer; Rebecca F Rosen; Amarallys Cintron; Lary C Walker
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 4.  Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies.

Authors:  Peter T Nelson; Elizabeth Head; Frederick A Schmitt; Paulina R Davis; Janna H Neltner; Gregory A Jicha; Erin L Abner; Charles D Smith; Linda J Van Eldik; Richard J Kryscio; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-04-24       Impact factor: 17.088

Review 5.  Vascular risk factors: imaging and neuropathologic correlates.

Authors:  David S Knopman; Rosebud Roberts
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

6.  A novel approach for integrative studies on neurodegenerative diseases in human brains.

Authors:  Panos Theofilas; Livia Polichiso; Xuehua Wang; Luzia C Lima; Ana T L Alho; Renata E P Leite; Claudia K Suemoto; Carlos A Pasqualucci; Wilson Jacob-Filho; Helmut Heinsen; Lea T Grinberg
Journal:  J Neurosci Methods       Date:  2014-02-03       Impact factor: 2.390

7.  Neuropathologic features associated with Alzheimer disease diagnosis: age matters.

Authors:  L E Middleton; L T Grinberg; B Miller; C Kawas; K Yaffe
Journal:  Neurology       Date:  2011-10-26       Impact factor: 9.910

Review 8.  Case Studies Illustrating Focal Alzheimer's, Fluent Aphasia, Late-Onset Memory Loss, and Rapid Dementia.

Authors:  Gamze Balci Camsari; Melissa E Murray; Neill R Graff-Radford
Journal:  Neurol Clin       Date:  2016-06-03       Impact factor: 3.806

9.  Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation.

Authors:  Lea Tenenholz Grinberg; Xuehua Wang; Chao Wang; Peter Dongmin Sohn; Panos Theofilas; Manu Sidhu; John Benjamin Arevalo; Helmut Heinsen; Eric J Huang; Howard Rosen; Bruce L Miller; Li Gan; William W Seeley
Journal:  Acta Neuropathol       Date:  2013-01-31       Impact factor: 17.088

Review 10.  Neurodegenerative disorders and nanoformulated drug development.

Authors:  Ari Nowacek; Lisa M Kosloski; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2009-07       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.